France Clinical Nutrition Market Analysis

France Clinical Nutrition Market Executive Summary

The France Clinical Nutrition Market is at around $843.4 Mn in 2023 and is projected to reach $11395.5 Mn in 2030, exhibiting a CAGR of 4.34% during the forecast period 2023-2030.

Clinical nutrition is the application of nutrition principles to promote health and prevent disease in individuals, particularly in a healthcare setting. It involves assessing patients' nutritional needs, creating personalized nutrition plans, and implementing evidence-based interventions to improve health outcomes. Clinical nutrition centres on the prevention, diagnosis, and management of nutritional changes in patients linked to chronic diseases and conditions primarily in health care. Clinical in this sense refers to the management of patients, including not only outpatients at clinics and in private practice, but also inpatients in hospitals. It incorporates primarily the scientific fields of nutrition and dietetics. Furthermore, clinical nutrition aims to maintain a healthy energy balance, while also providing sufficient amounts of nutrients such as protein, vitamins, and minerals to patients.

Clinical malnutrition refers to a condition that can be treated with clinical intervention by using specialized nutrients that are considered proper medications rather than as supplements. Clinical nutrition products are useful in maintaining the patient's health and enable the improvement of the body's metabolic system by providing adequate supplements, such as minerals, vitamins, and other supplements. The clinical nutrition sector is undergoing a transformation fuelled by progress in medical research and technology. Key trends such as innovative formulations, personalized nutrition solutions, and the use of bioactive ingredients are emerging. Manufacturers are dedicating resources to R&D to produce products that not only fulfil fundamental nutritional requirements but also provide added health advantages. This emphasis on innovation is fostering competition among industry participants, resulting in a constant flow of new products and therapies tailored to various patient demographics.

Clinical nutritionists or registered dietitians work in hospitals, clinics, and other healthcare facilities to, assess patients' nutritional status, develop personalized nutrition plans, provide nutrition education, manage nutrition-related diseases like diabetes, malnutrition etc, support optimal health and well-being. Some areas of focus in clinical nutrition include, critical care nutrition, paediatric nutrition, oncology nutrition, gastrointestinal nutrition, sports nutrition etc.

The most prevalent treated chronic diseases in France in 2019 was diabetes (6.0%), chronic respiratory diseases (5.5%), and coronary diseases (3.2%). Coronary diseases accounted for 4.6% of health expenditures, neurotic and mood disorders 3.7%, psychotic disorders 2.8%, and breast cancer 2.1%. The major drivers of Clinical Nutrition industry in France are, increasing prevalence of chronic diseases and metabolic disorders, aging population, increasing awareness of the importance of nutrition for health, product innovations and technological advancements, government initiatives and rising healthcare expenditure, rising incidence of malnutrition especially in paediatric patients.

The industry is primarily dominated by players such as Lactalis Health Nutrition, Laboratoires Gilbert, Abbott Nutrition, Pfizer Inc, Bayer AG, Nestle, Baxter International Inc, Ltd, Mead Johnson & Company, LLC among others.

Market Dynamics

Market Drivers

Aging population: France has an increasingly aging population, with the number of people aged 65 and over projected to rise from 13.4 Mn in 2021 to 15.3 Mn by 2030. Older adults are more susceptible to malnutrition, chronic diseases, and conditions that require specialized clinical nutrition support, driving demand.

Chronic disease prevalence: The prevalence of chronic diseases like diabetes, cancer, and cardiovascular diseases is rising in France. The most prevalent treated chronic diseases in France in 2019 was diabetes (6%), chronic respiratory diseases (5.5%), and coronary diseases (3.2%). Coronary diseases accounted for 4.6% of health expenditures, neurotic and mood disorders 3.7%, psychotic disorders 2.8%, and breast cancer 2.1%. These chronic conditions often require clinical nutrition interventions as part of disease management.

Consumer awareness: There is a growing health-conscious consumer base in France, with increasing awareness about the role of nutrition in maintaining wellness. This is driving demand for nutritional supplements and clinical nutrition products.

Market Restraints

Perception issues: Some healthcare providers and patients in France may have an imprecise understanding of the benefits of clinical nutrition, limiting its utilization. Educating the medical community and the public about the importance of clinical nutrition is crucial.

Regulatory challenges: Clinical nutrition products in France must be approved by the French Agency for Food, Environmental and Occupational Health & Safety (ANSES), which can be a lengthy and complex process. This can slow down the introduction of new clinical nutrition products in the market. Thus, hampering market growth rate.

Reimbursement changes: There are concerns about potential reductions in drug reimbursements in France, which could lead consumers to seek alternative, potentially less effective products. This could impact the clinical nutrition market.

Regulatory Landscape and Reimbursement Scenario

France's clinical nutrition regulation involves several key bodies working in concert. The French National Agency for Food, Environmental and Occupational Health Safety (ANSES) not only manages nutrition guidelines but also conducts risk assessments for food and nutrition-related health issues. The French National Authority for Health (HAS) plays a crucial role in evaluating medical technologies and procedures, including nutritional interventions, which directly influences reimbursement decisions. The French Agency for the Safety of Health Products (ANSM) rigorously oversees the pharmaceutical aspects of clinical nutrition, regulating the approval, manufacturing, and post-market surveillance of nutritional products classified as drugs or medical devices. This includes stringent oversight of enteral and parenteral nutrition formulas. The pharmaceutical industry engages with these bodies throughout the product lifecycle, from research and development to market authorization and pharmacovigilance.

Reimbursement is managed through the national health insurance system, with the Union Nationale des Caisses d'Assurance Maladie (UNCAM) at its helm. UNCAM negotiates prices with pharmaceutical companies and sets reimbursement rates based on therapeutic value and budget impact. For clinical nutrition, reimbursement levels are tiered: essential treatments like parenteral nutrition for chronic intestinal failure are fully covered, while other nutritional therapies may have varying levels of coverage. The Transparency Commission, part of HAS, assesses the medical benefit (SMR) and improvement in medical benefit (ASMR) of each product, which directly influences its reimbursement rate. This system ensures that innovative and high-value nutritional interventions can achieve favourable reimbursement status. Complementary private insurance often covers the patient's share of costs not reimbursed by the national system.

Competitive Landscape

Key Players

Here are some of the major key players in the France Clinical Nutrition Market:

• Lactalis Health Nutrition
• Laboratoires Gilbert
• Fresenius Kabi
• Abbott Nutrition
• Pfizer Inc.
• Bayer AG
• Nestle
• Baxter International Inc.
• Mead Johnson & Company, LLC
• Danone